10177-21-6

Basic information

• Product Name: CHEMPACIFIC 38137
• Synonyms: CHEMPACIFIC 38137;4-CHLORO-2-CHLOROMETHYL-PYRIDINE;Pyridine, 4-chloro-2-(chloromethyl)-
• CAS NO: 10177-21-6
• Molecular Formula: C₆H₅Cl₂N
• Molecular Weight: 162.02
• EINECS: 604-604-1
• Mol File: 10177-21-6.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 216.3°C at 760 mmHg
• Flash Point: 105.1°C
• Appearance: /
• Density: 1.324g/cm³
• Vapor Pressure: 0.207mmHg at 25°C
• Refractive Index: 1.55
• PKA: 2.01±0.10(Predicted)
• CAS DataBase Reference: CHEMPACIFIC 38137(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMPACIFIC 38137(10177-21-6)
• EPA Substance Registry System: CHEMPACIFIC 38137(10177-21-6)

Safety Data

• Hazardous Substances Data: 10177-21-6(Hazardous Substances Data)

Usage

Uses

4-Chloro-2-(chloromethyl)pyridine is an intermediate in the synthesis of 1-(4-Chloropyridin-2-yl)-N-methylmethanamine (C380680), which is used in the preparation of indole derivatives as inhibitors between MDM2 and p53 interactions.

InChI:InChI=1/C6H5Cl2N/c7-4-6-3-5(8)1-2-9-6/h1-3H,4H2

Upstream product

• 696-08-2 4-chloro-2-picoline-N-oxide 
• 63071-06-7 (4-chloropyridin-2-yl)methyl acetate 
• 24484-93-3 4-Chloro-pyridine-2-carboxylic acid methyl ester 
• 98-98-6 2-Picolinic acid 
• 1121-76-2 4-chloropyridine N-oxide 
• 5470-66-6 2-methyl-4-nitropyridine N-oxide 
• 931-19-1 2-methylpyridine N-oxide 
• 63071-10-3 (4-chloropyridin-2-yl)methanol 
• 20979-34-4 2-(chloromethyl)pyridine N-oxide hydrochloride 

Downstream Products

• 180748-30-5 (4-chloropyridin-2-yl)methanamine 
• 133928-61-7 N-phenyl-4-chloro-2-pyridinecarboxamide 
• 881205-08-9 4-chloro-2-methylaminomethylpyridine 
• 500716-28-9 2-(aminomethyl)-4-(dimethylamino)pyridine 
• 189153-29-5 Thiophosphoric acid O-[(2R,3S,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl] ester S-(4-chloro-pyridin-2-ylmethyl) ester O'-(2-cyano-ethyl) ester 
• 199597-32-5 Dithiophosphoric acid O-[(2R,3S,5R)-2-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl] ester S-(4-chloro-pyridin-2-ylmethyl) ester O'-(2-cyano-ethyl) ester 

Relevant articles and documents

Superoxide dismutase activity of iron(II)TPEN complex and its derivatives

Superoxide is involved in the pathogenesis of various diseases, such as inflammation, ischemia-reperfusion injury and carcinogenesis. Superoxide dismutases (SODs) catalyze the disproportionation reaction of superoxide to produce oxygen and hydrogen peroxide, and can protect living cells against the toxicity of free radicals derived from oxygen. Thus, SODs and their functional mimics have potential value as pharmaceuticals. We have previously reported that Fe(II)tetrakis-N,N,N',N'-(2-pyridylmethyl)ethylenediamine (Fe(II)TPEN) has an excellent SOD activity (IC50=0.5 μM) among many iron complexes examined (J. Biol. Chem., 264, 9243-9249 (1989)). Fe(II)TPEN can act like native SOD in living cells, and protect Escherichia coli cells from free radical toxicity caused by paraquat. In order to develop more effective SOD functional mimics, we synthesized Fe(II)TPEN derivatives with electron-donating or electron-withdrawing groups at the 4-position of all pyridines of TPEN, and measured the SOD activities and the redox potentials of these complexes. Fe(II) tetrakis-N,N,N',N'-(4-methoxy-2-pyridylmethyl)ethylenediamine (Fe(II)(4MeO)4TPEN) had the highest SOD activity (IC50=0.1 μM) among these iron-based SOD mimics. In addition, a good correlation was found between the redox potential and the SOD activity of 15 Fe(II) complexes, including iron-based SOD mimics reported in the previous paper (J. Organometal. Chem., in press). Iron-based SOD mimics may be clinically applicable, because these complexes are generally tissue-permeable and show low toxicity. Therefore our findings should be significant for the development of clinically useful SOD mimics.

THE PREPARATION OF 4- AND 6-CHLORO-2-CHLOROMETHYLPYRIDINE

6-Chloro-2-chloromethylpyridine is prepared from 6-chloro-2-methylpyridine by a route in which the 2-Me substituent was successively converted to 2-acetoxymethyl, 2-hydroxymethyl and finaly to the required 2-chloromethyl substituent.Attempts to simultaneously monochlorinate the Me group and reduce the N-oxide function of 6-chloro-2-methylpyridine-N-oxide with methanesulphonyl chloride and p-toluenesulphonyl chloride gave only very small yields of 6-chloro-2-chloromethyl-pyridine. 4-Chloro-2-chloromethylpyridine is prepared from 2-methylpyridine-N-oxide by nitration, followed by substitution of the 4-nitro group by chloro using conc HCl; side chain chlorination of the 2-Me group using p-toluenesulphonyl chloride yields 4-chloro-2-chloromethylpyridine.Phosphoryl chloride reacts with 2-chloromethylpyridine-N-oxide hydrochloride to yield only 14.4percent of 4-chloro-2-chloromethylpyridine, together with 2-chloromethylpyridine (2.2percent), 2-dichloromethylpyridine (41.6percent) and 6-chloro-2-chloromethylpyridine (41.8percent).Attempts to N-oxidise 2-chloromethylpyridine with peracids led to either 2-hydroxymethylpyridine (peracetic, m-chloroperbenzoic and performic acid) or no reaction (perfluoroacetic acid); none of the peracids led to any detectable N-oxidation.

DINUCLEATING LIGAND OR DINUCLEAR METAL COMPLEX

To provide a dinuclear metal complex that can be synthesized simply and easily and has a proper anticancer action.SOLUTION: The present disclosure provides a dinucleating ligand represented by the following formula (I) and a dinuclear metal complex thereof (where each X may be the same or different to represent H, Cl, OMe, or, Me, Y is H, a phenyl group, a substituted carbamoyl group or the like).SELECTED DRAWING: None

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.